Biotech entity
All 1 tracked stories fall under one category: fda-approval. Clene Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention CNM-Au8, all published on August 15, 2026.
Last mentioned: Aug 15, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: fda-approval. Clene Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention CNM-Au8, all published on August 15, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CNM-Au8. Shared-story counts are live from our verified record — not editorial picks.
Q2 2026 financial results reported
Laser Photonics reports net sales of $1.8 million and positive gross margin; Zeo reports 23% sequential revenue growth; Clene reports Q2 results and CNM-Au8 program updates.
Q2 2026 reporting period ends
Laser Photonics, Zeo Energy, and Clene complete the second quarter ended June 30, 2026.
FDA meeting minutes confirm accelerated approval pathway for CNM-Au8
Clene receives formal meeting minutes stating its proposed NfL data may be capable of supporting an NDA for CNM-Au8 in ALS under accelerated approval.
Clene Inc. reports FDA meeting minutes confirm an accelerated approval pathway for CNM-Au8 in ALS. New biomarker analyses link NfL stabilization to longer survival and improved function. The company plans to submit an NDA, citing data from two completed Phase 2 trials.
Source: californiatelegraph.com · hawaiitelegraph.com
CNM-Au8 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
